Trial Description: Patients with known ASCVD/heterozygous familial hypercholesterolemia (FH) on intensive/maximum-tolerated statin therapy with LDL-C > goal were randomized 2:1 to either bempedoic acid 180 mg daily or placebo and followed for 52 weeks.

RESULTS
• Primary endpoint: change in LDL-C from baseline for bempedoic acid vs. placebo: -15.1% vs. 2.4%, p < 0.001
• Change in hsCRP from baseline at week 12: -18.7% vs. -9.4%, p = 0.039
• 5-point MACE: 6.1% vs. 8.2%, p > 0.05; MI: 1.1% vs. 3.5%

CONCLUSIONS
• Bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with ASCVD or heterogeneous FH on maximum-tolerated statin therapy
• No difference was noted for clinical outcomes – trial was not powered for this

Presented by Dr. Anne C. Goldberg at ACC 2019